Differential angiogenic regulation of experimental colitis.

Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders of the intestinal tract with unknown multifactorial etiology that, among other things, result in alteration and dysfunction of the intestinal microvasculature. Clinical observations of increased colon microvascular density during IBD have been made. However, there have been no reports investigating the physiological or pathological importance of angiogenic stimulation during the development of intestinal inflammation. Here we report that the dextran sodium sulfate and CD4+CD45RBhigh T-cell transfer models of colitis stimulate angiogenesis that results in increased blood vessel density concomitant with increased histopathology, suggesting that the neovasculature contributes to tissue damage during colitis. We also show that leukocyte infiltration is an obligatory requirement for the stimulation of angiogenesis. The angiogenic response during experimental colitis was differentially regulated in that the production of various angiogenic mediators was diverse between the two models with only a small group of molecules being similarly controlled. Importantly, treatment with the anti-angiogenic agent thalidomide or ATN-161 significantly reduced angiogenic activity and associated tissue histopathology during experimental colitis. Our findings identify a direct pathological link between angiogenesis and the development of experimental colitis, representing a novel therapeutic target for IBD.

[1]  A. Linscott,et al.  Regulation of dextran sodium sulfate induced colitis by leukocyte beta 2 integrins , 2006, Laboratory Investigation.

[2]  J. Alexander,et al.  VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[3]  D. Ostanin,et al.  Role of T-cell-associated lymphocyte function-associated antigen-1 in the pathogenesis of experimental colitis. , 2006, International immunology.

[4]  Hidekazu Tomimoto,et al.  Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. , 2005, Blood.

[5]  M. Sharma,et al.  Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis , 2005, Histopathology.

[6]  Jürgen Schymeinsky,et al.  Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. , 2005, American journal of physiology. Heart and circulatory physiology.

[7]  F. Carraro,et al.  Role of inflammatory mediators in angiogenesis. , 2005, Current drug targets. Inflammation and allergy.

[8]  F. Powrie Immune Regulation in the Intestine: A Balancing Act between Effector and Regulatory T Cell Responses , 2004, Annals of the New York Academy of Sciences.

[9]  H. Goto,et al.  Immunomodulatory therapy for inflammatory bowel disease , 2004, Journal of Gastroenterology.

[10]  C. Kevil,et al.  CD18 deficiency protects against multiple low-dose streptozotocin-induced diabetes. , 2004, The American journal of pathology.

[11]  C. Fiocchi,et al.  Inflammatory Bowel Disease: Autoimmune or Immune-mediated Pathogenesis? , 2004, Clinical & developmental immunology.

[12]  Sumio Watanabe,et al.  Altered expression of angiogenic factors in the VEGF-Ets-1 cascades in inflammatory bowel disease , 2004, Journal of Gastroenterology.

[13]  Ulrich Schraermeyer,et al.  A central role for inflammation in the pathogenesis of diabetic retinopathy , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  D. Bullard,et al.  Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease. , 2004, The American journal of pathology.

[15]  Francis J. Martin,et al.  VEGF-mediated inflammation precedes angiogenesis in adult brain , 2004, Experimental Neurology.

[16]  S. Deventer,et al.  Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel disease , 2004, Journal of leukocyte biology.

[17]  D. Bullard,et al.  Intercellular Adhesion Molecule-1 (ICAM-1) Regulates Endothelial Cell Motility through a Nitric Oxide-dependent Pathway* , 2004, Journal of Biological Chemistry.

[18]  I. Cohen,et al.  Angiogenesis-Inflammation Cross-Talk: Vascular Endothelial Growth Factor Is Secreted by Activated T Cells and Induces Th1 Polarization , 2004, The Journal of Immunology.

[19]  H. Blau,et al.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. , 2004, The Journal of clinical investigation.

[20]  M. Farthing Severe Inflammatory Bowel Disease: Medical Management , 2003, Digestive Diseases.

[21]  Y. Ogura,et al.  Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease , 2003, Nature Medicine.

[22]  E. Maltezos,et al.  Vascular endothelial growth factor in inflammatory bowel disease , 2003, International Journal of Colorectal Disease.

[23]  F. Cominelli,et al.  Mouse models for the study of Crohn's disease. , 2003, Trends in molecular medicine.

[24]  L. Ellis,et al.  Inhibition of integrin α5β1 function with a small peptide (ATN‐161) plus continuous 5‐FU infusion reduces colorectal liver metastases and improves survival in mice , 2003, International journal of cancer.

[25]  David Zurakowski,et al.  Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Koteliansky,et al.  Collagen-binding integrin α1β1 regulates intestinal inflammation in experimental colitis , 2002 .

[27]  M. Abreu The pathogenesis of inflammatory bowel disease: Translational implications for clinicians , 2002, Current gastroenterology reports.

[28]  G. Porro,et al.  Inflammatory bowel disease: new insights into pathogenesis and treatment , 2002, Journal of internal medicine.

[29]  K. Müller,et al.  Expression of the endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitro. , 2002, Experimental and molecular pathology.

[30]  Thomas D. Wu,et al.  Gene Expression Profiling in silico: Relative Expression of Candidate Angiogenesis Associated Genes in Renal Cell Carcinomas , 2002, Nephron Experimental Nephrology.

[31]  G. Porro,et al.  The vascularity of internal fistulae in Crohn's disease: an in vivo power Doppler ultrasonography assessment , 2002, Gut.

[32]  Y. Mori,et al.  Differential roles of ICAM-1 and E-selectin in polymorphonuclear leukocyte-induced angiogenesis. , 2002, American journal of physiology. Cell physiology.

[33]  R. Hesketh,et al.  Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. , 2002, The American journal of pathology.

[34]  A. Wettstein,et al.  Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease , 2002, Journal of gastroenterology and hepatology.

[35]  H. Lochs,et al.  Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease , 2002, Gut.

[36]  S. Marcus,et al.  Activation of progelatinase A (MMP‐2) by neutrophil elastase, cathepsin G, and proteinase‐3: A role for inflammatory cells in tumor invasion and angiogenesis , 2001, Journal of cellular physiology.

[37]  R. Leek,et al.  The prognostic role of angiogenesis in breast cancer. , 2001, Anticancer research.

[38]  M. Grisham,et al.  Immunological Basis of Inflammatory Bowel Disease: Role of the Microcirculation , 2001, Microcirculation.

[39]  F. Peale,et al.  Gene profiling techniques and their application in angiogenesis and vascular development , 2001, The Journal of pathology.

[40]  F. Powrie,et al.  Control of intestinal inflammation by regulatory T cells. , 2001, Microbes and infection.

[41]  D. McDonald,et al.  Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. , 2001, The American journal of pathology.

[42]  S. Kanazawa,et al.  VEGF, basic-FGF, and TGF-β in Crohn’s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation , 2001 .

[43]  S. Kanazawa,et al.  VEGF, basic-FGF, and TGF-β in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation , 2001, American Journal of Gastroenterology.

[44]  M. Dubinsky,et al.  Doppler US in patients with crohn disease: vessel density in the diseased bowel reflects disease activity. , 2000, Radiology.

[45]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[46]  M. Adachi,et al.  Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA) , 2000, Clinical and experimental immunology.

[47]  F. Peale,et al.  Gene expression profiling in an in vitro model of angiogenesis. , 2000, The American journal of pathology.

[48]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[49]  Fiona Powrie,et al.  An Essential Role for Interleukin 10 in the Function of Regulatory T Cells That Inhibit Intestinal Inflammation , 1999, The Journal of experimental medicine.

[50]  D. Granger,et al.  Quantification of murine endothelial cell adhesion molecules in solid tumors. , 1999, American journal of physiology. Heart and circulatory physiology.

[51]  M. Lisanti,et al.  Angiogenesis Activators and Inhibitors Differentially Regulate Caveolin-1 Expression and Caveolae Formation in Vascular Endothelial Cells , 1999, The Journal of Biological Chemistry.

[52]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[53]  D. Granger,et al.  Expression of mucosal addressin cell adhesion molecule‐1 (MAdCAM‐1) in acute and chronic inflammation , 1999, Journal of leukocyte biology.

[54]  A. Bousvaros,et al.  Elevated Serum Vascular Endothelial Growth Factor in Children and Young Adults with Crohn's Disease , 1999, Digestive Diseases and Sciences.

[55]  Cooper,et al.  Combination therapy of pentoxifylline and TNFα monoclonal antibody in dextran sulphate‐induced mouse colitis , 1999, Alimentary pharmacology & therapeutics.

[56]  E. Levin,et al.  Extracellular Signal-regulated Protein Kinase/Jun Kinase Cross-talk Underlies Vascular Endothelial Cell Growth Factor-induced Endothelial Cell Proliferation* , 1998, The Journal of Biological Chemistry.

[57]  G. Majno Chronic inflammation: links with angiogenesis and wound healing. , 1998, The American journal of pathology.

[58]  A. Beaudet,et al.  Spontaneous Skin Ulceration and Defective T Cell Function in CD18 Null Mice , 1998, The Journal of experimental medicine.

[59]  J. Alexander,et al.  Vascular Permeability Factor/Vascular Endothelial Cell Growth Factor-mediated Permeability Occurs through Disorganization of Endothelial Junctional Proteins* , 1998, The Journal of Biological Chemistry.

[60]  D. Granger,et al.  Differential Expression of Platelet‐Endothelial Cell Adhesion Molecule‐1 (PECAM‐1) in Murine Tissues , 1998, Microcirculation.

[61]  J. Waltenberger,et al.  The Vascular Endothelial Growth Factor Receptor KDR Activates Multiple Signal Transduction Pathways in Porcine Aortic Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[62]  G. Garcı́a-Cardeña,et al.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.

[63]  Sartor Rb Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. , 1997 .

[64]  P. Carmeliet,et al.  Molecular analysis of blood vessel formation and disease. , 1997, American journal of physiology. Heart and circulatory physiology.

[65]  J. Alexander,et al.  An improved, rapid Northern protocol. , 1997, Biochemical and biophysical research communications.

[66]  C. Garlanda,et al.  Involvement of endothelial PECAM-1/CD31 in angiogenesis. , 1997, The American journal of pathology.

[67]  H. DeLisser,et al.  Neutrophil platelet endothelial cell adhesion molecule-1 participates in neutrophil recruitment at inflammatory sites and is down-regulated after leukocyte extravasation. , 1997, Journal of immunology.

[68]  D. Willoughby,et al.  The codependence of angiogenesis and chronic inflammation , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  A. Bousvaros,et al.  Serum Basic Fibroblast Growth Factor in Pediatric Crohn's Disease (Implications for Wound Healing) , 1997, Digestive Diseases and Sciences.

[70]  A. De Benedetti,et al.  Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis , 1996, International journal of cancer.

[71]  C. Elson,et al.  Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. , 1994, Gastroenterology.

[72]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Cord Sunderkötter,et al.  Macrophages and angiogenesis , 1994, Journal of leukocyte biology.

[74]  R. Coffman,et al.  Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. , 1993, International immunology.

[75]  S. Albelda,et al.  Expression of platelet‐endothelial cell adhesion molecule‐1 (PECAM‐1) during melanoma‐induced angiogenesis in vivo , 1993, Journal of cutaneous pathology.

[76]  G. Kaplan,et al.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.

[77]  A. Dalgleish,et al.  Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. , 2005, Microvascular research.

[78]  N. Ferrara The role of VEGF in the regulation of physiological and pathological angiogenesis. , 2005, EXS.

[79]  Y. Igarashi,et al.  Thalidomide-induced anti-angiogenic action is mediated by ceramide through depletion of VEGF receptors , and antagonized by sphingosine-1-phosphate , 2005 .

[80]  R. Chervenak,et al.  Regulation of chronic colitis in athymic nu/nu (nude) mice. , 2004, International immunology.

[81]  F. Powrie,et al.  Animal models of intestinal inflammation: clues to the pathogenesis of inflammatory bowel disease. , 2004, Novartis Foundation symposium.

[82]  R. D'Amato,et al.  Long-term remission of Crohn's disease treated with thalidomide: A seminal case report , 2004, Angiogenesis.

[83]  A. Harris,et al.  Macrophage infiltration and angiogenesis in human malignancy. , 2004, Novartis Foundation symposium.

[84]  G. Hospers,et al.  Platelets and Granulocytes, in Particular the Neutrophils, Form Important Compartments for Circulating Vascular Endothelial Growth Factor , 2004, Angiogenesis.

[85]  D. Creamer,et al.  Angiogenesis in psoriasis , 2004, Angiogenesis.

[86]  R. Colman,et al.  Experimental models of inflammatory bowel disease. , 2003, Archivum immunologiae et therapiae experimentalis.

[87]  V. Koteliansky,et al.  Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. , 2002, The Journal of clinical investigation.

[88]  B. Coll-Vinent,et al.  Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. , 2000, Arthritis and rheumatism.

[89]  M. Cassatella Neutrophil-derived proteins: selling cytokines by the pound. , 1999, Advances in immunology.

[90]  P. Polverini Role of the macrophage in angiogenesis-dependent diseases. , 1997, EXS.

[91]  R. Sartor Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. , 1997, The American journal of gastroenterology.

[92]  H. Granger,et al.  Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. , 1996, The American journal of physiology.

[93]  P. Morrissey,et al.  Induction of wasting disease in SCID mice by the transfer of normal CD4+/CD45RBhi T cells and the regulation of this autoreactivity by CD4+/CD45RBlo T cells. , 1994, Research in immunology.

[94]  T. Ohkusa,et al.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. , 1990, Gastroenterology.